Scars defaced

ScarX Corp. has reformulated a generic analgesic that is marketed primarily in Europe into a topical cream that patients can self-administer after surgery to prevent scarring. The company expects cosmetic and reconstructive surgeons to be early adopters of its topical nefopam, and thinks patients will pay out of pocket.

Nefopam is a non-opioid analgesic that is marketed in Europe, Australia and parts of Asia in oral or IV formulations to treat pain, but is not approved for use in North America. ScarX has exclusive rights from The Hospital for Sick Children to one issued patent and five patents pending covering the use of nefopam as an anti-scarring agent, and its topical formulation...